23andMe Terms of Service

This document governs US-based consumer access to 23andMe's DNA testing, ancestry, health reporting, membership, and telehealth services, establishing a binding contractual relationship between 23andMe Research Institute and users on the basis of continued service use. The agreement states that disputes must be resolved through binding individual arbitration administered by JAMS, explicitly waiving class action and jury trial rights, and authorizes 23andMe to modify terms at any time with notice via website posting or email, with continued use constituting acceptance. The arbitration clause includes a 30-day opt-out window for new users via written notice, and the no-refund policy applies except as required by applicable law, with sample processing failures governed by a tiered reprocessing protocol culminating in a full refund minus shipping for persistent failures. The terms engage HIPAA considerations given the collection and processing of genetic and health-related data, the FTC Act given consumer-facing data and privacy practices, CCPA given California residency provisions, and FDA regulations given the clinical health reporting features of certain services. The agreement's limitation of liability to fees paid in the prior 12 months for genetic and health services, combined with the class action waiver and mandatory arbitration, creates a dispute resolution structure that compliance teams operating in California, Illinois, or EU-adjacent contexts should evaluate under applicable consumer protection frameworks.